Brazil’s antitrust regulator CADE announced on Wednesday, January 20, it had cleared the way for Hypera Pharma to buy a portfolio of productions from Japan’s Takeda Pharmaceutical.
According to a source familiar with the matter, there was only one restriction, and it involved the medicine Xantinon, which Hypera has already sold locally to União Química Farmacêutica Nacional. Hypera had told investors it was expecting this approval in early 2021.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
